2016

What is $9.10 2016?

Idrofos 150 Tablet (Ibandronic Acid 150mg) is a bisphosphonate medication designed for the treatment and prevention of postmenopausal osteoporosis. It works by inhibiting bone resorption, helping to maintain bone strength and reduce the risk of fractures. Marketed under pricing references from 2016, this formulation is taken once monthly, offering a convenient dosing schedule for long-term bone health management.

Key features

• Active Ingredient — Contains 150mg ibandronic acid for effective bone resorption inhibition.
• Monthly Dosing — Once-a-month regimen improves patient compliance compared to daily treatments.
• Osteoporosis Management — Specifically indicated for postmenopausal women at risk of bone density loss.
• Prescription-Based — Requires medical supervision for safe and effective use.
• Oral Tablet — Easy-to-swallow formulation with standardized dosage.
• Manufactured for Women’s Health — Focused on hormonal-related bone density decline.
• Stable Pricing Reference — Historically priced around $9.10 per tablet, reflecting cost-effective long-term therapy.

Who is $9.10 2016 for?

This medication is intended for postmenopausal women diagnosed with or at high risk for osteoporosis. It's suitable for those seeking a monthly oral treatment to reduce bone breakdown and prevent fractures. Patients must be able to follow dosing instructions carefully, including remaining upright and fasting before intake, to minimize gastrointestinal risks.

How does $9.10 2016 compare?

Compared to daily bisphosphonates like alendronate, Idrofos 150 offers a more convenient monthly dosing schedule, improving adherence. It performs similarly to other ibandronate-based treatments in clinical outcomes but may carry a lower gastrointestinal burden due to less frequent use. Unlike injectable osteoporosis drugs, it avoids needles but requires strict oral administration rules. It is cost-competitive with other branded monthly oral therapies, especially when priced near $9.10 per dose.